抗好中球細胞質抗体（ANCA）関連血管炎の世界市場レポート 2025年

抗好中球細胞質抗体（ANCA）関連血管炎の市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は9.0％で、8億8,000万米ドルに成長します。予測期間中に予測される成長は、研究や臨床試験の拡大、研究開発活動の活発化、自己免疫疾患の罹患率の上昇、免疫系機能不全の症例の増加、様々な関連リスク因子の有病率の上昇などに起因すると考えられます。この期間に予想される主な動向には、個別化医療の台頭、戦略的提携、診断検査の進歩、遠隔医療の採用拡大、併用療法の開発などがあります。

自己免疫疾患の有病率の増加は、今後数年間におけるANCA関連血管炎市場の成長を促進すると予想されます。自己免疫疾患は、免疫システムが体内の健康な細胞や組織を、細菌やウイルスなどの有害な侵入者と間違えて攻撃することで発症します。これらの疾患の増加は、環境要因や現代の生活習慣に関連しており、感染症や汚染物質にさらされる機会が増えることは、免疫寛容を乱し、異常な免疫反応を誘発することで大きく寄与しています。ANCA関連血管炎は、標的免疫抑制療法の開発を促進し、早期診断能力を高め、全体的な疾患管理アプローチを洗練させることで、自己免疫疾患研究と治療の進歩にプラスの影響を与えます。このような進歩は、最終的には患者の転帰を改善し、免疫系の制御に関する深い洞察につながります。例えば、2023年9月、クローン病と潰瘍性大腸炎患者の生活改善を目的とするカナダを拠点とする組織、炎症性腸疾患（IBD）臨床研究センターが発表した「IBDの影響レポート2023」によると、2023年にはIBDはカナダ人10万人あたり825人、合計32万人以上に影響を及ぼすとされています。有病率は年間2.44%増加すると予想され、2035年にはカナダの人口の1.1%に相当する約47万人がIBDと共存することになります。その結果、自己免疫疾患の増加がANCA関連血管炎市場の拡大を支えることになります。

ANCA関連血管炎市場の主要企業は、この稀で重篤な疾患の患者に新たな治療選択肢を提供するため、標的治療薬などの革新的ソリューションの開発を優先しています。ANCA関連血管炎の標的療法は、炎症や血管損傷を引き起こす免疫成分を特異的に阻害する特殊な生物学的製剤を利用するもので、これにより疾患の進行を抑制し、従来の治療に関連する副作用を軽減します。例えば、2023年2月、スイスを拠点とする製薬会社Vifor Fresenius Medical Care Renal Pharma（VFMCRP）は、リツキシマブまたはシクロホスファミドベースのレジメンとの併用でANCA関連血管炎（AAV）を治療するTavneos（avacopan）について、オーストラリア政府の規制機関であるTherapeutic Goods Administration（TGA）から承認を取得しました。Tavneosは、ANCA関連血管炎の2つの主な病型である多発血管炎性肉芽腫症（GPA）および顕微鏡的多発血管炎（MPA）に特化して開発された初の標的治療薬であるため、今回の承認は重要なマイルストーンとなります。この治療薬は、補体C5a受容体（C5aR1）を選択的に阻害することによって作用し、長期にわたる深刻な副作用で知られる高用量のグルココルチコイド（ステロイド）への依存を減らしながら、炎症と疾患の進行を管理するのに役立ちます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の抗好中球細胞質抗体（ANCA）関連血管炎PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の抗好中球細胞質抗体（ANCA）関連血管炎市場：成長率分析
• 世界の抗好中球細胞質抗体（ANCA）関連血管炎市場の実績：規模と成長, 2019-2024
• 世界の抗好中球細胞質抗体（ANCA）関連血管炎市場の予測：規模と成長, 2024-2029, 2034F
• 世界の抗好中球細胞質抗体（ANCA）関連血管炎総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の抗好中球細胞質抗体（ANCA）関連血管炎市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 多発血管炎性肉芽腫症（GPAまたはウェゲナー肉芽腫症）
• 顕微鏡的多発血管炎（MPA）
• 好酸球性多発血管炎性肉芽腫症（EGPAまたはチャーグ・ストラウス病）
• その他のタイプ
• 世界の抗好中球細胞質抗体（ANCA）関連血管炎市場：治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 免疫抑制剤
• コルチコステロイド
• 生物学的製剤
• その他の治療法
• 世界の抗好中球細胞質抗体（ANCA）関連血管炎市場：診断別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血液検査
• 生検
• 画像診断
• その他の診断
• 世界の抗好中球細胞質抗体（ANCA）関連血管炎市場、多発血管炎性肉芽腫症（GPAまたはウェゲナー肉芽腫症）、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• 限局性多発血管炎性肉芽腫症
• 重症多発血管炎性肉芽腫症
• 難治性多発血管炎性肉芽腫症
• 世界の抗好中球細胞質抗体（ANCA）関連血管炎市場、顕微鏡的多発血管炎（MPA）、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• 腎顕微鏡的多発血管炎
• 肺顕微鏡的多発血管炎
• 神経学的顕微鏡的多発血管炎
• 世界の抗好中球細胞質抗体（ANCA）関連血管炎市場、好酸球性多発血管炎性肉芽腫症（EGPAまたはチャーグ・ストラウス病）、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• 心臓好酸球性肉芽腫症多発血管炎
• 肺好酸球性肉芽腫症多発血管炎
• 神経学的好酸球性多発血管炎性肉芽腫症
• 世界の抗好中球細胞質抗体（ANCA）関連血管炎市場、その他のタイプ、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬剤誘発性ANCA関連血管炎
• 感染関連ANCA関連血管炎
• オーバーラップ症候群ANCA関連血管炎

第7章 地域別・国別分析

• 世界の抗好中球細胞質抗体（ANCA）関連血管炎市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の抗好中球細胞質抗体（ANCA）関連血管炎市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 抗好中球細胞質抗体（ANCA）関連血管炎市場：競合情勢
• 抗好中球細胞質抗体（ANCA）関連血管炎市場：企業プロファイル
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Amgen Inc.
• Fresenius Medical Care（FMS）
• Boehringer Ingelheim International GmbH
• Otsuka Holdings Co. Ltd.
• Biogen Inc.
• Quest Diagnostics Inc
• Csl Behring AG
• ARUP Laboratories
• Sebia Inc.
• Exagen Inc.
• Argenx SE
• Arkana Laboratories
• Alentis Therapeutics AG
• Hansa Biopharma AB
• InflaRx NV

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 抗好中球細胞質抗体（ANCA）関連血管炎市場2029：新たな機会を提供する国
• 抗好中球細胞質抗体（ANCA）関連血管炎市場2029：新たな機会を提供するセグメント
• 抗好中球細胞質抗体（ANCA）関連血管炎市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Antineutrophil cytoplasmic antibody (ANCA) associated vasculitis is a rare autoimmune disorder marked by inflammation and damage to small and medium-sized blood vessels, primarily affecting organs such as the kidneys, lungs, and respiratory tract. If left untreated, it can lead to serious complications. This condition intersects with nephrology, pulmonology, and rheumatology, and requires a multidisciplinary approach involving immunosuppressive therapies, corticosteroids, and advanced treatment strategies to prevent organ failure and enhance long-term outcomes.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of ANCA-associated vasculitis include granulomatosis with polyangiitis (GPA or Wegener's), microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA or Churg-Strauss), and other variants. Granulomatosis with polyangiitis (GPA), previously known as Wegener's granulomatosis, is a systemic form of AAV characterized by granuloma formation and inflammation in small to medium-sized vessels, often impacting the respiratory system, kidneys, and other organs. Treatment options include immunosuppressants, corticosteroids, biologics, and other therapies, with diagnosis supported by blood tests, biopsies, imaging studies, and additional diagnostic tools.

The ANCA associated vasculitis market research report is one of a series of new reports from The Business Research Company that provides ANCA associated vasculitis market statistics, including ANCA associated vasculitis industry global market size, regional shares, competitors with a ANCA associated vasculitis market share, detailed ANCA associated vasculitis market segments, market trends and opportunities, and any further data you may need to thrive in the ANCA associated vasculitis industry. This ANCA associated vasculitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antineutrophil cytoplasmic antibody (ANCA) associated vasculitis market size has grown strongly in recent years. It will grow from $0.57 billion in 2024 to $0.63 billion in 2025 at a compound annual growth rate (CAGR) of 9.2%. The growth observed during the historic period can be attributed to increased healthcare expenditure, rising disposable income, a stronger focus on patient-centered care, an expanding middle-class population, greater adoption of telemedicine, and a growing geriatric population.

The antineutrophil cytoplasmic antibody (ANCA) associated vasculitis market size is expected to see strong growth in the next few years. It will grow to $0.88 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth projected during the forecast period can be attributed to expanding research and clinical trials, increased research and development activities, a rising incidence of autoimmune diseases, growing cases of immune system dysfunction, and a higher prevalence of various associated risk factors. Key trends expected during this period include the rise of personalized medicine, strategic collaborations, advancements in diagnostic testing, increased adoption of telemedicine, and the development of combination therapies.

The increasing prevalence of autoimmune diseases is anticipated to propel the growth of the ANCA-associated vasculitis market in the coming years. Autoimmune diseases occur when the immune system erroneously targets the body's own healthy cells and tissues, mistaking them for harmful invaders such as bacteria or viruses. The rise in these conditions is linked to environmental factors and modern lifestyle habits, with greater exposure to infections and pollutants significantly contributing by disturbing immune tolerance and triggering abnormal immune responses. ANCA-associated vasculitis positively influences advancements in autoimmune disease research and treatment by promoting the development of targeted immunosuppressive therapies, boosting early diagnostic capabilities, and refining overall disease management approaches. These advancements ultimately lead to improved patient outcomes and a deeper insight into immune system regulation. For example, in September 2023, the Impact of IBD Report 2023, published by the Inflammatory Bowel Disease (IBD) Clinical and Research Centre a Canada-based organization dedicated to improving the lives of those with Crohn's disease and ulcerative colitis stated that in 2023, IBD affected 825 per 100,000 Canadians, totaling over 320,000 individuals. With an anticipated annual growth rate of 2.44% in prevalence, it is estimated that by 2035, around 470,000 people, or 1.1% of the Canadian population, will be living with IBD. Consequently, the growing occurrence of autoimmune diseases will support the expansion of the ANCA-associated vasculitis market.

Leading companies in the ANCA-associated vasculitis market are prioritizing the development of innovative solutions such as targeted therapies to offer new treatment options for patients with this rare and severe disease. Targeted therapies for ANCA-associated vasculitis utilize specialized biologic agents that specifically inhibit immune components responsible for inflammation and blood vessel damage, thereby limiting disease advancement and reducing the side effects linked to conventional treatments. For instance, in February 2023, Vifor Fresenius Medical Care Renal Pharma (VFMCRP), a Switzerland-based pharmaceutical firm, received approval from the Therapeutic Goods Administration (TGA) an Australian government regulatory body for Tavneos (avacopan) to treat ANCA-associated vasculitis (AAV) in combination with rituximab or cyclophosphamide-based regimens. This approval is a significant milestone, as Tavneos is the first targeted treatment specifically developed for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), the two main forms of ANCA-associated vasculitis. The therapy works by selectively blocking the complement C5a receptor (C5aR1), helping to manage inflammation and disease progression while reducing dependence on high-dose glucocorticoids (steroids), which are known for their serious long-term side effects.

In March 2024, Q32 Bio Inc., a U.S.-based clinical-stage biotechnology company, merged with Homology Medicines, Inc. for an undisclosed sum. This merger enables Q32 Bio to enhance its standing as a publicly traded biotech firm by securing resources to further develop key biologic therapies such as bempikibart for autoimmune conditions including atopic dermatitis and alopecia areata, and ADX-097 for complement-mediated disorders, with a Phase 2 trial targeting ANCA-associated vasculitis scheduled for early 2025. Homology Medicines Inc. is a U.S.-based clinical-stage genetic medicines company specializing in treatments for rare diseases.

Major players in the antineutrophil cytoplasmic antibody (anca) associated vasculitis market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., AstraZeneca Plc, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Fresenius Medical Care (FMS), Boehringer Ingelheim International GmbH, Otsuka Holdings Co. Ltd., Biogen Inc., Quest Diagnostics Inc, Csl Behring AG, ARUP Laboratories, Sebia Inc., Exagen Inc., Argenx SE, Arkana Laboratories, Alentis Therapeutics AG, Hansa Biopharma AB, InflaRx NV.

North America was the largest region in the antineutrophil cytoplasmic antibody (ANCA) associated vasculitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the antineutrophil cytoplasmic antibody (ANCA) associated vasculitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The antineutrophil cytoplasmic antibody (ANCA) associated vasculitis market consists of revenues earned by entities by providing services such as diagnostic testing, disease management, and patient counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The antineutrophil cytoplasmic antibody (ANCA) associated vasculitis market also includes sales of biologic therapies, plasma exchange equipment, diagnostic test kits, targeted oral therapies, and monoclonal antibodies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antineutrophil cytoplasmic antibody (anca) associated vasculitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antineutrophil cytoplasmic antibody (anca) associated vasculitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antineutrophil cytoplasmic antibody (anca) associated vasculitis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Granulomatosis With Polyangiitis (GPA Or Wegener's); Microscopic Polyangiitis (MPA); Eosinophilic Granulomatosis With Polyangiitis (EGPA Or Churg-Strauss); Other Types
• 2) By Treatment: Immunosuppressants; Corticosteroids; Biologics; Other Treatments
• 3) By Diagnosis: Blood Tests; Biopsy; Imaging; Other Diagnosis
• Subsegments:
• 1) By Granulomatosis With Polyangiitis (GPA or Wegener's): Limited Granulomatosis With Polyangiitis; Severe Granulomatosis With Polyangiitis; Refractory Granulomatosis With Polyangiitis
• 2) By Microscopic Polyangiitis (MPA): Renal Microscopic Polyangiitis; Pulmonary Microscopic Polyangiitis; Neurological Microscopic Polyangiitis
• 3) By Eosinophilic Granulomatosis With Polyangiitis (EGPA or Churg-Strauss): Cardiac Eosinophilic Granulomatosis With Polyangiitis; Pulmonary Eosinophilic Granulomatosis With Polyangiitis; Neurological Eosinophilic Granulomatosis With Polyangiitis
• 4) By Other Types: Drug-Induced ANCA-Associated Vasculitis; Infection-Related ANCA-Associated Vasculitis; Overlap Syndrome ANCA-Associated Vasculitis
• Companies Mentioned: F. Hoffmann-La Roche AG; Thermo Fisher Scientific Inc. ; AstraZeneca Plc; Novartis AG; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Characteristics

3. Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Trends And Strategies

4. Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Growth Rate Analysis
• 5.4. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Total Addressable Market (TAM)

6. Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Segmentation

• 6.1. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Granulomatosis With Polyangiitis (GPA Or Wegener's)
• Microscopic Polyangiitis (MPA)
• Eosinophilic Granulomatosis With Polyangiitis (EGPA Or Churg-Strauss)
• Other Types
• 6.2. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunosuppressants
• Corticosteroids
• Biologics
• Other Treatments
• 6.3. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood Tests
• Biopsy
• Imaging
• Other Diagnosis
• 6.4. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Sub-Segmentation Of Granulomatosis With Polyangiitis (GPA Or Wegener's), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Limited Granulomatosis With Polyangiitis
• Severe Granulomatosis With Polyangiitis
• Refractory Granulomatosis With Polyangiitis
• 6.5. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Sub-Segmentation Of Microscopic Polyangiitis (MPA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Renal Microscopic Polyangiitis
• Pulmonary Microscopic Polyangiitis
• Neurological Microscopic Polyangiitis
• 6.6. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Sub-Segmentation Of Eosinophilic Granulomatosis With Polyangiitis (EGPA Or Churg-Strauss), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cardiac Eosinophilic Granulomatosis With Polyangiitis
• Pulmonary Eosinophilic Granulomatosis With Polyangiitis
• Neurological Eosinophilic Granulomatosis With Polyangiitis
• 6.7. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drug-Induced ANCA-Associated Vasculitis
• Infection-Related ANCA-Associated Vasculitis
• Overlap Syndrome ANCA-Associated Vasculitis

7. Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Regional And Country Analysis

• 7.1. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 8.1. Asia-Pacific Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 9.1. China Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 9.2. China Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 10.1. India Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 11.1. Japan Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 11.2. Japan Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 12.1. Australia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 13.1. Indonesia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 14.1. South Korea Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 14.2. South Korea Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 15.1. Western Europe Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 15.2. Western Europe Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 16.1. UK Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 17.1. Germany Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 18.1. France Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 19.1. Italy Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 20.1. Spain Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 21.1. Eastern Europe Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 21.2. Eastern Europe Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 22.1. Russia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 23.1. North America Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 23.2. North America Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 24.1. USA Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 24.2. USA Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 25.1. Canada Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 25.2. Canada Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 26.1. South America Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 26.2. South America Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 27.1. Brazil Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 28.1. Middle East Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 28.2. Middle East Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

• 29.1. Africa Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Overview
• 29.2. Africa Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Competitive Landscape And Company Profiles

• 30.1. Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Competitive Landscape
• 30.2. Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Other Major And Innovative Companies

• 31.1. Amgen Inc.
• 31.2. Fresenius Medical Care (FMS)
• 31.3. Boehringer Ingelheim International GmbH
• 31.4. Otsuka Holdings Co. Ltd.
• 31.5. Biogen Inc.
• 31.6. Quest Diagnostics Inc
• 31.7. Csl Behring AG
• 31.8. ARUP Laboratories
• 31.9. Sebia Inc.
• 31.10. Exagen Inc.
• 31.11. Argenx SE
• 31.12. Arkana Laboratories
• 31.13. Alentis Therapeutics AG
• 31.14. Hansa Biopharma AB
• 31.15. InflaRx NV

32. Global Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

34. Recent Developments In The Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market

35. Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market High Potential Countries, Segments and Strategies

• 35.1 Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34761_Antineutrophil_Cytoplasmic_Antibody_ANCA_Associated_Vasculitis_GMR_2025